Table 2.
Survival outcomes
| n | OS | RFS | |||||
|---|---|---|---|---|---|---|---|
| 3-y (95% CI) | Adjusted HR (95% CI)* | P * | 3-y (95% CI) | Adjusted HR (95% CI)* | P * | ||
| Donor type | |||||||
| MUD | 974 | 0.48 (0.45, 0.52) | Reference | .43 | 0.42 (0.39, 0.45) | Reference | .60 |
| Haplo | 487 | 0.43 (0.38, 0.49) | 1.09 (0.89, 1.33) | 0.39 (0.34, 0.44) | 1.05 (0.87, 1.27) | ||
| Recipient age, y | |||||||
| <30 | 579 | 0.53 (0.49, 0.57) | Reference | <.001 | 0.48 (0.43, 0.52) | Reference | <.001 |
| 30-39 | 281 | 0.47 (0.40, 0.53) | 1.29 (1.06, 1.57) | 0.40 (0.33, 0.46) | 1.32 (1.09, 1.60) | ||
| 40-54 | 350 | 0.46 (0.40, 0.51) | 1.34 (1.11, 1.61) | 0.42 (0.36, 0.47) | 1.29 (1.08, 1.54) | ||
| ≥55 | 251 | 0.34 (0.28, 0.41) | 1.92 (1.50, 2.45) | 0.27 (0.21, 0.33) | 1.83 (1.43, 2.34) | ||
| KPS † | |||||||
| 90-100 | 978 | 0.51 (0.47, 0.54) | Reference | <.001 | 0.44 (0.40, 0.47) | Reference | <.001 |
| ≤80 | 388 | 0.36 (0.31, 0.41) | 1.51 (1.28, 1.79) | 0.33 (0.28, 0.38) | 1.35 (1.15, 1.58) | ||
| ALL subtype | |||||||
| B-ALL | 1044 | 0.48 (0.44, 0.51) | Reference | .71 | 0.42 (0.39, 0.45) | Reference | .68 |
| T-ALL | 322 | 0.46 (0.40, 0.52) | 1.00 (0.82, 1.22) | 0.38 (0.33, 0.44) | 1.08 (0.90, 1.30) | ||
| Other | 95 | 0.41 (0.30, 0.52) | 1.12 (0.84, 1.50) | 0.38 (0.26, 0.49) | 1.00 (0.74, 1.35) | ||
| Months from diagnosis to HCT | |||||||
| ≤6 | 398 | 0.55 (0.50, 0.61) | Reference | .33 | 0.47 (0.41, 0.52) | Reference | .68 |
| >6-12 | 510 | 0.50 (0.45, 0.55) | 1.15 (0.95, 1.38) | 0.47 (0.43, 0.52) | 1.05 (0.88, 1.24) | ||
| >12 | 553 | 0.38 (0.33, 0.42) | 1.15 (0.92, 1.45) | 0.31 (0.27, 0.35) | 1.10 (0.89, 1.37) | ||
| HCT Comorbidity Index † | |||||||
| 0 | 147 | 0.57 (0.45, 0.67) | Reference | .14 | 0.43 (0.31, 0.55) | Reference | .30 |
| 1-2 | 92 | 0.28 (0.16, 0.43) | 1.52 (0.95, 2.42) | 0.29 (0.18, 0.42) | 1.34 (0.89, 2.02) | ||
| >2 | 94 | 0.42 (0.27, 0.57) | 0.95 (0.61, 1.49) | 0.39 (0.25, 0.53) | 0.95 (0.66, 1.36) | ||
| Donor age, y † | |||||||
| <30 | 342 | 0.44 (0.38, 0.50) | Reference | .62 | 0.39 (0.33, 0.45) | Reference | .45 |
| 30-49 | 443 | 0.47 (0.42, 0.52) | 0.97 (0.80, 1.17) | 0.42 (0.37, 0.47) | 0.96 (0.81, 1.15) | ||
| ≥50 | 127 | 0.45 (0.35, 0.55) | 1.11 (0.80, 1.55) | 0.41 (0.31, 0.50) | 1.12 (0.84, 1.50) | ||
| Female donor to male recipient † | |||||||
| No | 1172 | 0.47 (0.44, 0.50) | Reference | .86 | 0.41 (0.38, 0.44) | Reference | .54 |
| Yes | 262 | 0.47 (0.40, 0.54) | 0.98 (0.81, 1.19) | 0.39 (0.32, 0.45) | 1.06 (0.89, 1.25) | ||
| CMV serostatus † | |||||||
| D+/R+ | 581 | 0.46 (0.41, 0.50) | Reference | .41 | 0.39 (0.35, 0.44) | Reference | .63 |
| D+/R− | 130 | 0.49 (0.39, 0.57) | 0.96 (0.75, 1.23) | 0.46 (0.37, 0.54) | 0.94 (0.74, 1.21) | ||
| D−/R+ | 366 | 0.47 (0.41, 0.53) | 0.90 (0.73, 1.11) | 0.43 (0.37, 0.48) | 0.88 (0.73, 1.07) | ||
| D−/R− | 318 | 0.50 (0.44, 0.56) | 0.83 (0.67, 1.04) | 0.41 (0.35, 0.47) | 0.97 (0.80, 1.18) | ||
| Stem cell source | |||||||
| PB | 1056 | 0.48 (0.45, 0.51) | Reference | .082 | 0.42 (0.38, 0.45) | Reference | .074 |
| BM | 405 | 0.44 (0.38, 0.49) | 1.18 (0.98, 1.42) | 0.39 (0.34, 0.44) | 1.18 (0.98, 1.42) | ||
| Transplant period | |||||||
| 2005-2012 | 695 | 0.47 (0.43, 0.50) | Reference | .80 | 0.42 (0.38, 0.46) | Reference | .52 |
| 2013-2018 | 766 | 0.46 (0.42, 0.51) | 0.98 (0.83, 1.16) | 0.39 (0.35, 0.44) | 1.05 (0.90, 1.22) | ||
*
Based on the multivariable Cox regression model adjusted for recipient age, KPS, and stem cell source, and stratified by matching variables: sex, cytogenetic risk, Ph status, disease stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
†
Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.